We’re guessing International Podcast Day (9/30) passed you by with little fanfare. But we took note and are using the opportunity to highlight the power of podcasts. Celebrate with us by perusing our more than 100 episodes addressing a variety of accounting and reporting challenges.
This week you’ll find the final edition of our summer What’s next? podcast series, helping educate finance teams on ways to emerge stronger from the crisis. Look back on our 16 episodes for insights from a variety of our subject matter experts. And stay tuned for What’s next: tech. Our fall series will explore new technologies and the related considerations for finance professionals.
You’ve got questions? We have answers. Hear responses to the most common questions asked during our Q3 accounting webcast.
Heading into the 2020 election, business leaders must anticipate policy and regulatory shifts, and understand the potential impact on their businesses. Join members of PwC’s leadership team on Wednesday, October 14 at noon ET to learn more. Register today.
On September 30, the FASB voted to defer the effective date of the long-duration insurance contracts standard by one year and to allow a choice of transition dates if early adoption is elected. A final ASU is expected later this fall.
Today’s boardrooms are facing a new level of challenges. Find out how forward-thinking boards found ways to inspire positive change. This year’s results can help you benchmark against peers on critical topics like crisis management, ESG, diversity & inclusion, and board refreshment.
Read PwC’s comments on the FASB’s proposed ASU on determining the price of an underlying share for stock option awards, a proposal of the Private Company Council.
As private organizations reconsider leases to fit changing needs, they’re likely to look at the same contracts that will need to be reviewed again when adopting ASC 842. We explain how combining those efforts supports a “one and done” approach to evaluating leases.
The COVID-19 pandemic has upended clinical trials for pharmaceutical and life sciences companies. In our Q3 edition, we discuss how companies are adapting to the change and summarize recent accounting and regulatory developments.